22,729
Participants
Start Date
September 30, 2009
Primary Completion Date
January 31, 2017
Study Completion Date
July 31, 2026
Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)
The participants received either one, two or three doses of the avaccine. Each injection contains 20 microgram type 6, 40 microgram type 11, 40 microgram type 16, and 20 microgram type 18.
All India Institute of Medical Sciences, New Delhi
MNJ Institute of Oncology & Regional Cancer Center, Hyderabad
Christian Fellowship Community Health Centre, Ambilikkai
Cancer Foundation of India, Kolkata
Gujarat Cancer & Research Institute (GCRI), Ahmedabad
Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Barshi
Tata Memorial Center, Tata Memorial Hospital & Cancer Research Inst, Mumbai
Jehangir Clinical Development Centre (JCDC) Pvt. Ltd., Pune
All India Institute of Medical Sciences
OTHER
Cancer Foundation of India
OTHER
Christian Fellowship Community Health Centre
OTHER
German Cancer Research Center
OTHER
Gujarat Cancer & Research Institute
OTHER
Jehangir Clinical Development Centre
OTHER
MNJ Institute of Oncology and Regional Cancer Center
OTHER_GOV
Rajiv Gandhi Centre for Biotechnology
INDUSTRY
Nargis Datta Memorial Cancer Hospital
OTHER
Tata Memorial Centre
OTHER
Partha Basu
OTHER